Repurposing Antiparasitics for Cancer Treatment

For the past year and a half,

I've been working with antiparasitics that are being repurposed for cancer.

This is ivermectin, mebendazole, and fenbendazole.

And the reason is because there's a big body of research.

There are over 400 published papers on ivermectin in cancer.

There are over 240 published papers on mebendazole in cancer.

In fact, Johns Hopkins

quietly secured a patent in 2021 on mebendazole for treatment in cancer,

specifically the most aggressive cancer, which is glioblastoma, brain cancer, extremely aggressive cancer.

Johns Hopkins has the patent.

They are also running quietly several clinical trials with mebendazole in cancer.

There's colon cancer,

gastric cancer, and brain cancer, including children with brain cancers as well.

So this is not fringe.

This is not something that is far out.

There's actually real science behind it, patents behind it.

And when you search a lot of the AIs,

for example, perplexity AI, and you ask, what are the most promising repurposed drugs for terminally ill cancer patients today?

It will give you in its search in the top three,

you will get ivermectin as number one, mebendazole, and fenbendazole.

There's other antiparasitics like hydroxychloroquine will be in the top 10.

You will have curcumin in the top 10.

You will have EGCG, which is from a green tea extract in the top 10,

resveratrol in the top 10,

metformin, which is a diabetes drug, but also has anti-cancer activity in the top 10 as well.

And what I have found working with these antiparasitics is that there is a benefit

to patients in at least 75% of the cases.